Antiphospholipid syndrome (APS) is an autoimmune disease characterized by a hypercoagulable state in the setting of detectable antiphospholipid antibodies (APL). Notably, APS often presents alongside systemic lupus erythematosus (SLE), manifesting as secondary APS (SAPS) in approximately 70% of cases, while also occurring independently as primary APS (PAPS). The etiopathogenesis of the disease is only partially understood. While APS has traditionally been viewed as devoid of primary inflammatory processes, recent findings suggest otherwise. The lack of cellular inflammatory infiltration in the vessels occluded by a thrombus became even one of the criteria characterizing pathology typical for APS as opposed to vasculitic (inflammatory) features of SLE and ANCA-associated vasculitides (AAV). However, some studies highlight the potential influence of complement-mediated complications in APS, such as pregnancy failure, and propose inflammatory infiltrates as contributors to APS nephropathy. These insights indicate a closer functional relationship between coagulation and the immune system than previously acknowledged, warranting a comprehensive reassessment of APS pathology.

This Research Topic aims to investigate the interplay between thrombotic and inflammatory processes within APS, which may contribute significantly to its pathogenesis and diverse clinical outcomes. By examining these complex mechanisms, the research seeks to illuminate novel therapeutic avenues that could offer relief to treatment-resistant patients, particularly those with high-risk APL patterns or arterial thrombosis. A key objective is to assess the necessity for supplemental therapies beyond long-term anticoagulation with vitamin K antagonists.

To gather further insights into the multifaceted nature of APS and its association with lupus, we welcome articles addressing, but not limited to, the following themes:

o The role of inflammation and complement activation in APS development.

o The potential for additional therapies beyond standard anticoagulation for APS management.

o Exploration of novel biomarkers for APS diagnosis and risk stratification.

o Multidisciplinary strategies for managing obstetric APS.

o Implications of the 2023 ACR/EULAR classification criteria on APS diagnosis and treatment.

o Influence of genetic and epigenetic factors on APS pathogenesis and progression.

o Assessment of SLE development risk in patients with primary APS.

o Development of APS in SLE patients who were initially serologically negative.

We encourage contributions in the form of original research, reviews, and case analyses to foster a robust dialogue on expanding APS treatment strategies and understanding the link between APS and lupus beyond traditional thrombosis paradigms.

Impact

Frontiers in Lupus

Translational Immunology and Pre-Clinical Models

Participating Journals

Frontiers in Immunology

Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders